First Russian Budesonide + Formoterol Aerosol Inhaler Now Available
Russian patients with bronchial asthma now have access to the first domestically produced combination of budesonide + formoterol in aerosol inhaler form. PSK Pharma became the first Russian company to register this high-demand combination in an aerosol inhaler format for asthma treatment.
Previously, the combination was only available as a dry powder inhaler. The new product, Respiforb® Air, will be manufactured at PSK Pharma’s high-tech facility. Each inhaler delivers 120 doses and will be available with or without a dose counter.
The use of dual combinations (ICS/LABA) is a global and domestic trend in asthma treatment.
Budesonide + formoterol is the most prescribed combination and can be used from age six. It acts on both key mechanisms of asthma – inflammation and airway smooth muscle dysfunction.
The introduction of combination drugs for maintenance therapy in bronchial asthma has enabled a broad spectrum of patients across all age groups to effectively control their symptoms and live normal lives free from flare-ups and hospitalizations.
The launch of Respiforb® Air allows for flexible delivery options, especially for patients who cannot use dry powder inhalers due to physiological constraints or intolerance to excipients.
"In 2024, the Russian market for budesonide + formoterol aerosol inhalers totaled over 190,000 packages. We are happy that PSK Pharma's manufacturing capacity ensures consistent supply of modern, high-quality inhalers to Russian patients with bronchial asthma, backed by thorough bio- and clinical equivalency studies," stated Evgenia Shapiro, General Director of PSK Pharma.
The company’s pulmonology portfolio includes 22 products for asthma and COPD. The combination is also available as Respiforb® in single-dose powder inhaler form.